Christopher Hoimes
Duke University(US)Duke Medical Center(US)Duke Cancer Institute
Publications by Year
Research Areas
Cancer Immunotherapy and Biomarkers, Bladder and Urothelial Cancer Treatments, Vitamin C and Antioxidants Research, Cancer, Lipids, and Metabolism, Urinary and Genital Oncology Studies
Most-Cited Works
- → Efficacy and Safety of Durvalumab in Locally Advanced or Metastatic Urothelial Carcinoma(2017)842 cited
- → Pembrolizumab for Treatment-Refractory Metastatic Castration-Resistant Prostate Cancer: Multicohort, Open-Label Phase II KEYNOTE-199 Study(2019)688 cited
- → Bladder Cancer, Version 3.2020, NCCN Clinical Practice Guidelines in Oncology(2020)623 cited
- → Management of Immunotherapy-Related Toxicities, Version 1.2019, NCCN Clinical Practice Guidelines in Oncology(2019)554 cited
- → Bladder Cancer, Version 5.2017, NCCN Clinical Practice Guidelines in Oncology(2017)278 cited
- → A Phase II Trial of the Aurora Kinase A Inhibitor Alisertib for Patients with Castration-resistant and Neuroendocrine Prostate Cancer: Efficacy and Biomarkers(2018)269 cited